title: Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients.
abstract: BACKGROUND
  ³¹Phosphorous magnetic resonance spectroscopy (2D chemical shift imaging, CSI) allows multiregional study of membrane phospholipids and high-energy phosphates in vivo. Increased membrane lipid turnover and impaired energy supply have repeatedly been shown in first-episode schizophrenia patients, and might be a target of drug actions other than dopamine receptors. Here, we explored differential metabolic effects of a typical vs. an atypical antipsychotic on brain phospholipids.
  
  
  METHODS
  We applied 2D-CSI MR spectroscopy in 17 recurrent-episode schizophrenia patients off antipsychotics at baseline and at follow-up after 6 weeks, during which 7 patients were treated with haloperidol (10-16 mg/d) and 10 with risperidone (4-6 mg/d). Psychopathology changes were assessed using PANSS, BPRS and CGI scores.
  
  
  RESULTS
  Follow-up analysis using repeated measure ANOVA revealed different effects of both antipsychotic agents: while risperidone generally increased metabolite levels, haloperidol showed a tendency to decrease them. This diverging effect was significant for ATP levels in the left lateral frontal cortex. Furthermore, risperidone increased ATP in the left dorsolateral prefrontal cortex, left anterior temporal cortex and left insular cortex, basal ganglia, and anterior cerebellum, along with left frontal and prefrontal increase of PCr, PDE and PME in these brain regions.
  
  
  CONCLUSIONS
  Risperidone seems to stimulate neuronal and synaptic phospholipid remodeling in left frontal and prefrontal regions, and to a lesser extent also in temporal and insular cortices. We discuss these effects with respect to clinical effects on negative and cognitive symptoms, as well as interaction of phospholipid metabolism with glutamatergic neurotransmission.
authors.affiliation: Department of Psychiatry and Psychotherapy, Jena University Hospital, Friedrich-Schiller-University, Philosophenweg 3, D-07743 Jena, Germany. Stefan.Smesny@med.uni-jena.de
authors.forename: Stefan
authors.initials: S
authors.lastname: Smesny
authors.forename: Kerstin
authors.initials: K
authors.lastname: Langbein
authors.forename: Reinhardt
authors.initials: R
authors.lastname: Rzanny
authors.forename: Alexander
authors.initials: A
authors.lastname: Gussew
authors.forename: Hartmut P
authors.initials: HP
authors.lastname: Burmeister
authors.forename: Juergen R
authors.initials: JR
authors.lastname: Reichenbach
authors.forename: Heinrich
authors.initials: H
authors.lastname: Sauer
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001479:Basal Ganglia / Q000187:drug effects* / Q000378:metabolism; D002531:Cerebellum / Q000187:drug effects* / Q000378:metabolism; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006220:Haloperidol / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008563:Membrane Lipids / Q000378:metabolism; D008875:Middle Aged; D010743:Phospholipids / Q000378:metabolism; D010759:Phosphorus Isotopes; D018967:Risperidone / Q000494:pharmacology* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D008563:Membrane Lipids; D010743:Phospholipids; D010759:Phosphorus Isotopes; D006220:Haloperidol; D018967:Risperidone